Our latest research, all in one place. Browse our collection of journal articles, reports and conference proceedings to see how we’re contributing to HEOR research. Remember to:
A vision-based patient monitoring system (VBPMS), Oxevision, has been introduced in approximately half of National Health Service (NHS) mental health trusts in England. A VBPMS is an assistive tool that supports patient safety by enabling non-contact physiological and physical monitoring. The system aims to help staff deliver safer, higher-quality and more efficient care. This paper summarises the potential health economic impact of using a VBPMS to support clinical practice in two inpatient settings: acute mental health and older adult mental health services. The economic model used a cost calculator approach to evaluate the potential impact of introducing a VBPMS into clinical practice, compared with clinical practice without a VBPMS. The analysis captured the cost differences in night-time observations, one-to-one continuous observations, self-harm incidents, and bedroom falls at night, including those resulting in A&E visits and emergency service callouts. The analysis is based on before and after studies conducted at five mental health NHS trusts, including acute mental health and older adult mental health services. Our findings indicate that the use of a VBPMS results in more efficient night-time observations and reductions in one-to-one observations, self-harm incidents, bedroom falls at night, and A&E visits and emergency service callouts from night-time falls. Substantial staff time in acute mental health and older adult mental health services is spent performing night-time observations, one-to-one observations, and managing incidents. The use of a VBPMS could lead to cost savings and a positive return on investment for NHS mental health trusts. The results do not incorporate all of the potential benefits associated with the use of a VBPMS, such as reductions in medication and length of hospital stay, plus the potential to avoid adverse events which would otherwise have a detrimental impact on a patient's quality of life.
INTRODUCTION
Single use medical devices' environmental impact is known to generate sizable carbon emissions over a life cycle compared to a reusable equivalent. The SHTG have recognised the need to evaluate this health technology carbon hotspot as part of the HTA. Specifically, this environmental assessment was appropriate for parallel evaluation alongside a health economic analysis to support the decision-making process.
METHODS
Through the application of HTA and environmental management principles and reporting, the Greenhouse Gas (GHG) Protocols, ISO14040 and Publicly Available Specification 2050, a carbon footprint of single use rhinolaryngoscopes was compared with a reusable equivalent. Process activity data, real world data and secondary data were used to quantify carbon intensity. Data were extrapolated to estimate national GHG emissions and waste volumes. The technologies were categorized using thresholds based on the functional unit, to strengthen support for the HTA decision making process. Sensitivity analyses were performed. Further recommendations were made to promote the use of more sustainable health technologies.
RESULTS
The carbon emissions of a single use flexible rhinolaryngoscope compared to its reusable equivalent was 6.03kgCO2e and 3.26kgCO2e respectively. Data extrapolation (2264 procedures per annum) reveals the annual environmental impact of this technology, throughout NHS Scotland, to be 13,652kgCO2e and 7,381kgCO2e, for the single use and reusable devices, respectively. Raw material acquisition, the use of personal protective equipment and transportation were health technology carbon hotspots. The estimated waste volumes are 12.58 tonnes and negligible volumes of clinical waste per annum for the single use versus reusable equivalent, respectively. This pilot study recommends the use a reusable equivalent in this setting.
CONCLUSIONS
Aligned with NHS net zero targets, these findings confirm the need to perform a parallel environmental assessment of technologies alongside a HTA. LCA is a useful framework to comprehensively assess environmental impact of health technology. Data constraints can be overcome through the use of hybrid methodologies, aligned with HTA principles including transparency and reproducibility to enable sustainable HTA decision making.
Statistical analyses are common practice in the modern world. While statistics is a discipline in its own right, statistical methods are employed across a vast and growing range of fields. It is, therefore, essential that the sharing of statistical information can be adapted to meet the needs of a range of audiences.
A web application (app) is an app that is accessed using a web browser. An advantage of web apps is their accessibility, allowing multiple users to access the same app from different locations, devices and software platforms. Shiny is a free, open-source R package for developing web apps. Shiny provides an excellent opportunity to share results from analyses with others in an interactive, easy-to-build web app.
A Shiny app contains a user interface (ui) and a server function. These two objects interact with each other to create an interactive Shiny app. The ui element controls the layout and appearance of your app whereas the server object performs the necessary computations. While Shiny dashboards can be built using the Shiny package alone, the Shinydashboard package can be used to make it much easier to create a more visually appealing dashboard. This package enables the use of complex dashboards with a variety of complex layouts.
While producing a web app in Shiny requires good knowledge of the R programming language, for those already conducting their analyses in R, Shiny offers the opportunity to create a bespoke, high-quality dashboard that is accessible to the end user.
No abstract available.
BACKGROUND: Highly active (HA) relapsing remitting multiple sclerosis (RRMS) is associated with frequent relapses and high burden of disease/disability. Natalizumab is licensed for HA RRMS, including rapidly evolving severe (RES) (=2 relapses in previous year) and sub-optimally treated (SOT) (=1 relapse in previous year despite treatment) populations. However, there is limited RCT evidence in the SOT subpopulation.
OBJECTIVE: To review the non-RCT evidence for natalizumab in SOT HA RRMS.
METHODS: Databases were searched to January 2023 for non-randomised studies of natalizumab in HA RRMS. Studies in patients with =1 relapse during previous treatment were eligible for inclusion. Meta-analyses were conducted to compare natalizumab with platform and higher efficacy disease-modifying therapies, with sensitivity analysis restricted to studies of low risk of bias.
RESULTS: Included comparative studies (n = 16) showed natalizumab had lower relapse rates, disease activity and MRI (radiological) outcomes compared with platform and higher efficacy therapy. Case series (n = 11) showed natalizumab was associated with high rates of freedom from relapse and clinical/radiological disease activity and reductions in annualised relapse rate and disability progression.
CONCLUSIONS: Literature reviewed indicates that natalizumab is more effective than other included treatments for SOT patients. Findings were consistent with studies in the broad HA RRMS population, suggesting that natalizumab may have similar efficacy for SOT and RES HA RRMS.
